Immix Biopharma Initiated with Overweight Rating by Morgan Stanley
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IMMX?
Source: seekingalpha
- Rating Upgrade: Morgan Stanley initiated coverage on Immix Biopharma (IMMX) with an Overweight rating and a $20 price target, reflecting the analyst's strong optimism about its lead candidate NXC-201, which is expected to drive stock price appreciation.
- Clinical Trial Progress: NXC-201 is currently undergoing the mid-stage NEXICART-2 trial for relapsed/refractory AL amyloidosis, a rare disease with no approved therapies, highlighting the drug's market potential and clinical need.
- FDA Approval Outlook: With Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA, NXC-201 is poised for potential accelerated approval in the U.S., enhancing its market competitiveness and commercial value.
- Revenue Projections: The analyst projects approximately $802 million in peak risk-adjusted revenue for NXC-201 in R/R AL amyloidosis, with final pivotal data expected in H2 2026, followed by an FDA marketing application and a projected product launch in H1 2027.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMX
Wall Street analysts forecast IMMX stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.570
Low
8.00
Averages
8.00
High
8.00
Current: 8.570
Low
8.00
Averages
8.00
High
8.00
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immix Biopharma Initiated with Overweight Rating by Morgan Stanley
- Rating Upgrade: Morgan Stanley initiated coverage on Immix Biopharma (IMMX) with an Overweight rating and a $20 price target, reflecting the analyst's strong optimism about its lead candidate NXC-201, which is expected to drive stock price appreciation.
- Clinical Trial Progress: NXC-201 is currently undergoing the mid-stage NEXICART-2 trial for relapsed/refractory AL amyloidosis, a rare disease with no approved therapies, highlighting the drug's market potential and clinical need.
- FDA Approval Outlook: With Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA, NXC-201 is poised for potential accelerated approval in the U.S., enhancing its market competitiveness and commercial value.
- Revenue Projections: The analyst projects approximately $802 million in peak risk-adjusted revenue for NXC-201 in R/R AL amyloidosis, with final pivotal data expected in H2 2026, followed by an FDA marketing application and a projected product launch in H1 2027.
See More
Latest Rating Changes on Wall Street
- Tesla Neutral Rating: Goldman Sachs maintains a neutral stance on Tesla, expressing caution regarding its semiconductor ventures, noting a mixed track record in semiconductor engineering, while suggesting potential applications for inference chips in data centers and distributed computing remain to be seen.
- Upgrade Based on Iran War: Wells Fargo upgrades Kinetik, ONEOK, and Enterprise Products Partners from equal weight to overweight, anticipating that the Iran war will create a structural shift in global energy markets, boosting demand for U.S. energy, particularly in Permian gas and NGL supply.
- ESCO Technologies Buy Initiation: Deutsche Bank initiates coverage on ESCO Technologies with a Buy rating and a $350 target price, highlighting its potential for “defensive growth at a discount” in the aerospace and defense sectors, indicating strong confidence in the company's future.
- Arm Rating Upgrade: Wolfe upgrades Arm from market perform to outperform, citing the company's recent in-house chip launch and significantly increased earnings forecasts for FY28 and FY31, setting a target price of $166, reflecting optimism about its new business model.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Updates: While specific upgrades, downgrades, and initiations are not detailed in this article, the overall trend suggests fluctuations in analyst confidence, potentially prompting investors to reassess their stock holdings.
- Investor Consideration: For those considering buying VAL stock, analysts' opinions will serve as a crucial reference point, likely impacting their investment decisions and the stock's market performance.
- Market Dynamics Impact: Changes in analyst ratings typically provoke market reactions, necessitating investors to closely monitor these shifts to adjust their investment strategies accordingly.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrade and downgrade details are not provided, such changes typically have a direct impact on the stock prices of the affected companies, necessitating investor vigilance regarding these developments.
- Market Reaction Expectations: The adjustments in analysts' ratings may lead to increased buying or selling activity for TFC stock, thereby affecting its trading volume and price fluctuations in the short term.
- Investor Focus: Investors considering purchasing TFC stock should take into account the latest analyst ratings and market sentiment to make more informed investment decisions.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Focus: For those considering buying AKTS stock, analysts' opinions will serve as a crucial reference point, aiding in the assessment of investment risks and potential returns.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, even though specific rating details are not available.
See More
NXC-201 Receives FDA Breakthrough Therapy Designation
- FDA Designation: NXC-201 has been granted Breakthrough Therapy Designation by the FDA based on positive interim results from the NEXICART-2 clinical trial, marking a significant advancement in treating relapsed/refractory AL Amyloidosis.
- Clinical Trial Progress: The NEXICART-2 trial is expected to enroll 40 patients with a registrational design, aiming to expedite the development of NXC-201, with plans for a Biologics License Application (BLA) submission this year to bring the therapy to market swiftly.
- Market Potential: The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is projected to reach 38,500 by 2026, growing at a rate of 12% per year, providing a robust demand foundation for the market introduction of NXC-201.
- Industry Impact: The AL Amyloidosis market was valued at $3.6 billion in 2017 and is expected to grow to $6 billion by 2025, and the successful launch of NXC-201 will help Immix Biopharma secure a leading position in this rapidly expanding market.
See More
Immix Biopharma Initiated with Overweight Rating by Morgan Stanley
- Rating Upgrade: Morgan Stanley initiated coverage on Immix Biopharma (IMMX) with an Overweight rating and a $20 price target, reflecting the analyst's strong optimism about its lead candidate NXC-201, which is expected to drive stock price appreciation.
- Clinical Trial Progress: NXC-201 is currently undergoing the mid-stage NEXICART-2 trial for relapsed/refractory AL amyloidosis, a rare disease with no approved therapies, highlighting the drug's market potential and clinical need.
- FDA Approval Outlook: With Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA, NXC-201 is poised for potential accelerated approval in the U.S., enhancing its market competitiveness and commercial value.
- Revenue Projections: The analyst projects approximately $802 million in peak risk-adjusted revenue for NXC-201 in R/R AL amyloidosis, with final pivotal data expected in H2 2026, followed by an FDA marketing application and a projected product launch in H1 2027.
See More
Latest Rating Changes on Wall Street
- Tesla Neutral Rating: Goldman Sachs maintains a neutral stance on Tesla, expressing caution regarding its semiconductor ventures, noting a mixed track record in semiconductor engineering, while suggesting potential applications for inference chips in data centers and distributed computing remain to be seen.
- Upgrade Based on Iran War: Wells Fargo upgrades Kinetik, ONEOK, and Enterprise Products Partners from equal weight to overweight, anticipating that the Iran war will create a structural shift in global energy markets, boosting demand for U.S. energy, particularly in Permian gas and NGL supply.
- ESCO Technologies Buy Initiation: Deutsche Bank initiates coverage on ESCO Technologies with a Buy rating and a $350 target price, highlighting its potential for “defensive growth at a discount” in the aerospace and defense sectors, indicating strong confidence in the company's future.
- Arm Rating Upgrade: Wolfe upgrades Arm from market perform to outperform, citing the company's recent in-house chip launch and significantly increased earnings forecasts for FY28 and FY31, setting a target price of $166, reflecting optimism about its new business model.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Updates: While specific upgrades, downgrades, and initiations are not detailed in this article, the overall trend suggests fluctuations in analyst confidence, potentially prompting investors to reassess their stock holdings.
- Investor Consideration: For those considering buying VAL stock, analysts' opinions will serve as a crucial reference point, likely impacting their investment decisions and the stock's market performance.
- Market Dynamics Impact: Changes in analyst ratings typically provoke market reactions, necessitating investors to closely monitor these shifts to adjust their investment strategies accordingly.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrade and downgrade details are not provided, such changes typically have a direct impact on the stock prices of the affected companies, necessitating investor vigilance regarding these developments.
- Market Reaction Expectations: The adjustments in analysts' ratings may lead to increased buying or selling activity for TFC stock, thereby affecting its trading volume and price fluctuations in the short term.
- Investor Focus: Investors considering purchasing TFC stock should take into account the latest analyst ratings and market sentiment to make more informed investment decisions.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Focus: For those considering buying AKTS stock, analysts' opinions will serve as a crucial reference point, aiding in the assessment of investment risks and potential returns.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, even though specific rating details are not available.
See More
NXC-201 Receives FDA Breakthrough Therapy Designation
- FDA Designation: NXC-201 has been granted Breakthrough Therapy Designation by the FDA based on positive interim results from the NEXICART-2 clinical trial, marking a significant advancement in treating relapsed/refractory AL Amyloidosis.
- Clinical Trial Progress: The NEXICART-2 trial is expected to enroll 40 patients with a registrational design, aiming to expedite the development of NXC-201, with plans for a Biologics License Application (BLA) submission this year to bring the therapy to market swiftly.
- Market Potential: The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is projected to reach 38,500 by 2026, growing at a rate of 12% per year, providing a robust demand foundation for the market introduction of NXC-201.
- Industry Impact: The AL Amyloidosis market was valued at $3.6 billion in 2017 and is expected to grow to $6 billion by 2025, and the successful launch of NXC-201 will help Immix Biopharma secure a leading position in this rapidly expanding market.
See More
